The under-40s: How does the next generation of biopharma executives view the future?
A group of outstanding up-and-coming biopharma professionals under 40 talk about their jobs, their plans and their dreams — and some of the things that just have to change about this industry.
The young standouts featured here have worked hard to get where they are, and they’re nowhere near finished. If you’re looking for a common theme, it’s about making a difference — in a big way — in how people will deal with disease in the future. Together, they are thinking about groups of millions that all have to be stripped down to one single case at a time.
Mentors figure prominently for many on the list, with gratitude for the help and positive guidance in mapping careers that have decades to run. And it’s influencing how they deal with the generation coming up from behind.
No one is denying the risks involved. They’re not keen on tradition. And they all like to surround themselves with smart, savvy colleagues.
But more than anything, this is a story about working to change biopharma for the better — both a revolution and an evolution. That may be about pushing new tech that can deliver dramatic improvements in R&D and development programs, new attitudes about work and life, or working toward the day when thorny issues like gender diversity are dealt with once and for all.
None of it will be easy. But they have decades to fulfill their dreams.
7,000 words remain in this article. Please sign-in or subscribe to continue reading.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 65,700+ biopharma pros reading Endpoints daily — and it's free.